Oncology
Voiant is the leading clinical imaging partner for oncology trials.
As the new leader formed by the union of three best-in-class companies in clinical imaging, Voiant is the powerful solution that combines oncology expertise and imaging endpoint technology to deliver the highest quality imaging data required for regulatory filings.
Over 350 oncology trials under our belt, an experienced team, and a purpose-built AI-Software platform, make us the leading oncology imaging partner for BICR.
Oncology Imaging Expertise
Patient focus is at the heart of everything we do. As global leaders in oncology clinical trial imaging services, we bring over 30 years of experience in Phase I-IV trials, including pivotal studies. The experience and expertise of our team allows Voiant to specialize in standard read criteria such as RECIST 1.1. and associated modified read criteria, as well as IO read criteria in skin and other solid tumor indications.
Indications
Our team has provided imaging CRO services on more than 350 Oncology clinical trials across indications including:
- Acute lymphocytic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Bladder cancer
- Brain cancer
- Breast cancer
- Chronic lymphocytic leukemia (CLL)
- Colon cancer
- Colorectal cancer (CRC)
- Endometrial cancer
- Gastric cancer
- Glioblastoma: HGG, LGG
- Head and neck cancer
- Hepatocellular carcinoma
- Liver cancer
- Lymphoma
- Melanoma
- Multiple myeloma
- Neuroblastoma
- Non-small and small cell lung cancer (NSCLC,SCLC)
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Renal cell carcinoma (RCC)
- Bone Metastasis
- Sarcomas
- Cutaneous Squamous Cell carcinoma
- Thyroid cancer
- Urothelial cancer
- Uveal Melonoma
Evaluation Criteria
Voiant has extensive experience with studies involving various type of evaluations criteria, including:
- RECIST 1.1
- Lugano Classification
- Cheson 1999, 2007
- iRECIST
- Choi
- FDG and novel radiotracer quantitative and semi-quantitative assessments
- irRECIST
- IWG
- Macdonald
- mRECIST
- PCWG2/PCWG3
- RANO
- Tumor Volumetrics
- WHO
- LYRIC
- RANO-BM
Novel Imaging Biomarkers
Voiant is a leader in the field of novel Image based Biomarker development and implementation into clinical trials to enrich eligibility criteria and early Endpoints to support accelerated drug discovery and targeted local therapy. Voiant can partner with clients Biomarker programs to integrate image features with other clinical and molecular target.
Radiomics
- Volume
- Shape and Contour Features
- Intensity Features
- Texture Features
- Lesion Heterogeneity
- Rate of lesion size change
Additional MRI
- ADC
- Blood Volume
- Perfusion and Permeability
- T2& Fat water mapping
Additional PET
- Dynamic suv measures
- Total Lesion Glycolysis
- Metabolic Tumor Volume
AI-Powered Excellence in
Oncology Imaging Technology
Our software platform, accessible from anywhere in the world, integrates AI to provide high quality efficacy and safety data. Efficient AI supported image submission and quality control, read and data extraction workflows, enables Voiant to meet your critical submission timetable. Thousands of clinical sites in the U.S., Latin America, UK, Europe, and Asia-Pacific have uploaded imaging data directly into our secure system.
We provide computer-aided detection analysis for the following criteria:
- Lesion LDI & SDI (Longest and Shortest Diameters)
- Enhancing and non-enhancing volume
- Nuclear Medicine endpoints including SUV derivatives
- Bone scan lesion area (BSLA)
- Bone scan index (BSI)
- DWI/ADC
- Radiomics
Voiant’s technology platform uses AI technology to guide its users through key steps in image analysis:
- Image transfer and quality control checks
- PHI detection and removal
- Selection of best image(s) for analysis
Voiant’s fully configurable, highly scalable platform can be accessed anywhere, on any device, for scan tracking, adaptive reads, periodic reporting, and custom reader notifications.
Contact us
Experience the future of imaging in clinical trials. Schedule an exploratory discussion to learn more about our solutions.